The chapter holds the source skeleton.
articles · clauses · principlesThis page does not flatten Good AI Practice into a generic checklist. It identifies the specific source units that future interpretation, evidence objects, and public artifacts must trace back to.
FDA/EMA Good AI Practice principles
Common principles for AI in drug development released in January 2026.
EMA/HMA AI lifecycle reflection
Medicinal-product lifecycle context for AI use and risk management.
FDA AI drug development page
US source hub for AI in drug-development activity.
GMLP medical-device principles
Comparator source for device ML development; separate from medicines AI.
Context-of-use principle
The same model can carry different risk depending on decision context.
Lifecycle management principle
Model performance, change, and monitoring remain active after deployment.
Protected material stays protected.
citation not copyingUse source-owner titles, status, and public summaries; do not reproduce protected standards or paid guide content.
cite · summarise · trace · do not copy
Current public sources for Good AI Practice.
official firstThese links are the public source anchors for this workspace. Interpretation, checklists, and future assets should point back here before being reused outside iFeed.
FDA guiding principles for Good AI Practice in drug development
2026-01-14 · FDA page for common Good AI Practice principles in drug development.
EMA and FDA common AI principles news
2026-01-14 · EU-facing publication context for the common principles.
EMA/HMA AI in medicinal product lifecycle
2024-09-30 · Broader medicinal-product lifecycle reflection layer for AI use and governance.
FDA/Health Canada/MHRA GMLP principles
2021-10-27 · Ten guiding principles for Good Machine Learning Practice for medical device development.